DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Tokyo Big Sight

2018 年 11 月 11 日 9:30 上午 - 2018 年 11 月 13 日 5:40 下午

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

15th DIA Japan Annual Meeting 2018

Innovative technologies such as AI, big data/genomics, and cell/gene therapies are poised to transform healthcare product development across the globe – join us to discuss these topics.

[V7-S5] Pharmacovigilance Activities in Japan, the USA, and Europe - How to Utilize Real World Data -

Session Chair(s)

Hisashi  Urushihara, DrPH

Hisashi Urushihara, DrPH

Professor, Faculty of Pharmacy, Department of Pharmacy

Keio University, Japan

The 2018 GPSP revision allows the marketing authorization holders to select database studies including EHRs, claims records, and registries as the pharmacovigilance activities in Japan, changing the post-marketing regulatory climate. This session introduces the actual examples of effective use of real world data (RWD) in Western countries for the purpose of pharmacovigilance and discuss the challenges and policies to make effective use of RWD available in Japan.

Speaker(s)

Hisashi  Urushihara, DrPH

Introduction

Hisashi Urushihara, DrPH

Keio University, Japan

Professor, Faculty of Pharmacy, Department of Pharmacy

Gerald  Dal Pan, MD, MHS

Effective Use of RWD in FDA for Pharmacovigilance

Gerald Dal Pan, MD, MHS

FDA, United States

Director, Office of Surveillance and Epidemiology, CDER

Agnès  Saint-Raymond, DrMed

Effective Use of RWD in EMA for Pharmacovigilance

Agnès Saint-Raymond, DrMed

European Medicines Agency, Netherlands

Head of Division International Affairs

Takashi  Ando

Effective Use of RWD in PMDA for Pharmacovigilance

Takashi Ando

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Office of Medical Informatics and Epidemiology

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。